Glaucoma Therapeutics Market is Expected to Witness Healthy Growth at 4.7% CAGR through 2031

The glaucoma therapeutics market revenue will likely total US$ 6.6 Bn for 2021, according to Fact.MR. Overall, the market is expected to reach US$ 10 Bn by 2031, expanding 1.5x across the forthcoming decade. Demand for beta-blockers drug class will accelerate, anticipated to register a CAGR of 4.7% from 2021-2031.

This Report also provides the market survey of Glaucoma Therapeutics gives estimations of the Size of Glaucoma Therapeutics Market and the overall Glaucoma Therapeutics Market share of key regional segments During Forecast Period.

The latest industry analysis and survey on Glaucoma Therapeutics provides sales outlook in 20+ countries, across key categories. Insights and outlook on Glaucoma Therapeutics market drivers, trends, and influencing factors are also included in the study.

Click Here To get a Sample Report (Including Full TOC, Table & Figures):-

Key Segments Covered

  • Drug Class
    • Prostaglandins
    • Beta Blockers
    • Alpha Agonists
    • Carbonic Anhydrase Inhibitors
    • Combination Medications
    • Cholinergic Medications
  • End User
    • Hospitals
    • Ophthalmic Clinics
    • Ambulatory Surgical Centers

Need More information about Report Methodology? Click here:-

Key Parameters analyzed while estimating the Glaucoma Therapeutics market include:

  • To analyze Drugs/ Therapeutic Area in Glaucoma Therapeutics :

Overall Population by age group/Prevalence or Incidence of any disease/Treatment Seeking Rate/Dosage pattern/Average duration of treatment/Overall treatment cost and Reimbursement are considered.

  • To analyze Consumables of Glaucoma Therapeutics:

Overall Population/Prevalence or Incidence of disease/treatment seeking rate/ average duration of the treatment/average number of devices used per patient / average number of procedure per device/ average selling price per device/reimbursement are considered.

  • To analyze Glaucoma Therapeutics Equipment:

Number of Healthcare facilities (Hospitals/Ambulatory Surgical Centers/Clinics etc.)

Average number of devices installed per facilities/ lifespan of the devices/replacement rate of the equipment/new sales of the equipment per year/average selling price per equipment are considered.

Moreover, it also gives meaningful as well as actionable insights on the competitive analysis of Glaucoma Therapeutics Market that are developing the current market scenario and which will be lucrative for the future demand of Glaucoma Therapeutics Market.

Crucial insights in Glaucoma Therapeutics market research report:

  • Underlying macro- and microeconomic factors impacting the Sales of Glaucoma Therapeutics market.
  • Basic overview of the Glaucoma Therapeutics, including market definition, classification, and applications.
  • Scrutinization of each market player based on mergers & acquisitions, R&D projects, and product launches.
  • Adoption trend and supply side analysis of Glaucoma Therapeutics across various industries.
  • Important regions and countries offering lucrative opportunities to market stakeholders.

The Demand of Glaucoma Therapeutics Market study includes the current market scenario on the global platform and also Sales of Glaucoma Therapeutics Market development during the forecast period.

To get all-in insights on the regional landscape of the Glaucoma Therapeutics Market, buy now:-

Competitive Landscape

Strategic collaborations enable manufacturers to increase production and meet consumer demand which will increase revenue and market share. New products and technologies will enable end-users to benefit from products that are eco-friendly by nature. Key developments in the market are as follows:

  • In May 2020, the U.S Food & Drug Administration approved Allergan Plc.’s DURYSTATM (bimatoprost implant) New Drug Application. The drug is amongst the first intracameral, sustained-release implant indicated to reduce intraocular pressure (IOP) in patients with open-angle glaucoma, or ocular hypertension
  • In October 2021, Novartis AG pledged to work with partners all around the world to help eliminate preventable visual impairment and blindness by reimagining access to eye care. The company has partnered with the International Agency for the Prevention of Blindness during the World Sight Day to initiate the #LoveYourEyes campaign

More Related Reports by Fact.MR on Healthcare Sector: 

Sterile Compounding Pharmacies Market :-_ Sterile Compounding Pharmacies Market Growth to Spur with Rising Demand for Injectables during 2021-2031

Testosterone Nasal Gels Market:- Testosterone Nasal Gels Market Share Analysis By Indication, By Dosage (5mg, 10mg), By Distribution Channel & By Region Forecast, 2021-2031

Wireless Handheld Ultrasound Devices Market:- Small Size and Easy to Operate Functions to Boost the Sales of Wireless Handheld Ultrasound Devices during 2021-2031


The Market insights of Glaucoma Therapeutics will improve the revenue impact of businesses in various industries by:

  • Providing a framework tailored toward understanding the attractiveness quotient of various products/solutions/technologies in the Glaucoma Therapeutics Market
  • Guiding stakeholders to identify key problem areas pertaining to their consolidation strategies in the global Glaucoma Therapeutics market and offers solutions
  • Assessing the impact of changing regulatory dynamics in the regions in which companies are keen on expanding their footprints
  • Provides understanding of disruptive technology trends to help businesses make their transitions smoothly
  • Helping leading companies make strategy recalibrations ahead of their competitors and peers
  • Offers insights into promising synergies for top players aiming to retain their leadership position in the market & supply side analysis of Glaucoma Therapeutics market .

Browse More Reports by Fact.MR : –

About Fact.MR:

Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.

US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583

Corporate Headquarter:
Unit No: AU-01-H Gold Tower (AU),
Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers,
Dubai, United Arab Emirates